{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:49:04Z","timestamp":1793317744659,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-024-00281-7","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:12:33Z","timestamp":1731129153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer"],"prefix":"10.1186","volume":"10","author":[{"given":"Magdalena","family":"Zaborowska-Szmit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Olszyna-Serementa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Zajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Janowicz-\u017bebrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ja\u015bkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz M.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"issue":"17","key":"281_CR1","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.7150\/jca.26008","volume":"9","author":"Y Li","year":"2018","unstructured":"Li Y, Shang Y, Wang W, Ning S, Chen H. Lung cancer and pulmonary embolism: what is the relationship? Rev J Cancer. 2018;9(17):3046\u201357.","journal-title":"Rev J Cancer"},{"issue":"10","key":"281_CR2","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902\u20137.","journal-title":"Blood"},{"issue":"16","key":"281_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. 2023;41(16):3063\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"281_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Jara-Palomares L, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Sinn M, Syrigos K, Young A, Jordan K, ESMO Guidelines Committee. Venous thromboembolism in cancer patients: ESMO Clinical practice guideline. Ann Oncol. 2023;34(5):452\u201367.","journal-title":"Ann Oncol"},{"issue":"1","key":"281_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","volume":"8","author":"AA Khorana","year":"2022","unstructured":"Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, Moik F, Lee AYY. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11.","journal-title":"Nat Rev Dis Primers"},{"issue":"34","key":"281_CR6","doi-asserted-by":"publisher","first-page":"100739","DOI":"10.1016\/j.lanepe.2023.100739","volume":"28","author":"HT S\u00f8rensen","year":"2023","unstructured":"S\u00f8rensen HT, Pedersen L, van Es N, B\u00fcller HR, Horv\u00e1th-Puh\u00f3 E. Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study. Lancet Reg Health Eur. 2023;28(34):100739.","journal-title":"Lancet Reg Health Eur"},{"issue":"12","key":"281_CR7","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, Fuereder T, Z\u00f6chbauer-M\u00fcller S, Preusser M, Pabinger I, Ay C. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137(12):1669\u201378.","journal-title":"Blood"},{"issue":"4","key":"281_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","volume":"41","author":"SP Grover","year":"2021","unstructured":"Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer therapy-associated thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(4):1291\u2013305.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"31","key":"281_CR9","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1200\/JCO.2011.40.1810","volume":"30","author":"J Ahlbrecht","year":"2012","unstructured":"Ahlbrecht J, Dickmann B, Ay C, Dunkler D, Thaler J, Schmidinger M, Quehenberger P, Haitel A, Zielinski C, Pabinger I. Tumor grade is associated with venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2012;30(31):3870\u20135.","journal-title":"J Clin Oncol"},{"issue":"10","key":"281_CR10","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1093\/annonc\/mdm284","volume":"18","author":"M Mandal\u00e0","year":"2007","unstructured":"Mandal\u00e0 M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, Berardi R, Mosconi S, Torri V, Labianca R. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol. 2007;18(10):1660\u20135.","journal-title":"Ann Oncol"},{"issue":"25","key":"281_CR11","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","volume":"29","author":"RA Moore","year":"2011","unstructured":"Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, Soff G, Parameswaran R, Hassoun H. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29(25):3466\u201373.","journal-title":"J Clin Oncol"},{"issue":"14","key":"281_CR12","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, B\u00fcller HR, S\u00f8rensen HT. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959\u201369.","journal-title":"Blood"},{"issue":"5","key":"281_CR13","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/jcm9051268","volume":"9","author":"M Zaborowska-Szmit","year":"2020","unstructured":"Zaborowska-Szmit M, Krzakowski M, Kowalski DM, Szmit S. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med. 2020;9(5):1268.","journal-title":"J Clin Med"},{"issue":"14","key":"281_CR14","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2217\/fon.15.47","volume":"11","author":"A Tartarone","year":"2015","unstructured":"Tartarone A, Gallucci G, Lazzari C, Lerose R, Lombardi L, Aieta M. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. Future Oncol. 2015;11(14):2043\u20138.","journal-title":"Future Oncol"},{"issue":"11","key":"281_CR15","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/cncr.28040","volume":"119","author":"SH Ou","year":"2013","unstructured":"Ou SH, Tong WP, Azada M, Siwak-Tapp C, Dy J, Stiber JA. Heart rate decrease during crizotinib treatment and potential correlation to clinical response. Cancer. 2013;119(11):1969\u201375.","journal-title":"Cancer"},{"issue":"3","key":"281_CR16","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00280-017-3253-5","volume":"79","author":"PN Morcos","year":"2017","unstructured":"Morcos PN, Bogman K, Hubeaux S, Sturm-Pellanda C, Ruf T, Bordogna W, Golding S, Zeaiter A, Abt M, Balas B. Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies. Cancer Chemother Pharmacol. 2017;79(3):559\u201368.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"281_CR17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","volume":"17","author":"SN Gettinger","year":"2016","unstructured":"Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial. Lancet Oncol. 2016;17(12):1683\u201396.","journal-title":"Lancet Oncol"},{"issue":"21","key":"281_CR18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ, CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018\u201329.","journal-title":"N Engl J Med"},{"issue":"41","key":"281_CR19","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"1","key":"281_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.thromres.2012.10.007","volume":"131","author":"G Gussoni","year":"2013","unstructured":"Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M, RIETE Investigators. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013;131(1):24\u201330.","journal-title":"Thromb Res"},{"issue":"4","key":"281_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jim\u00e9nez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, N\u00ed \u00c1inle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL, ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543\u2013603.","journal-title":"Eur Heart J"},{"issue":"13","key":"281_CR22","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","volume":"14","author":"JP Koivunen","year":"2008","unstructured":"Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, J\u00e4nne PA. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275\u201383.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"281_CR23","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1158\/1078-0432.CCR-13-0318","volume":"19","author":"JF Gainor","year":"2013","unstructured":"Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273\u201381.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"281_CR24","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1001\/jama.2014.3741","volume":"311","author":"MG Kris","year":"2014","unstructured":"Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998\u20132006.","journal-title":"JAMA"},{"issue":"6","key":"281_CR25","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1093\/oncolo\/oyad061","volume":"28","author":"O Icht","year":"2023","unstructured":"Icht O, Leader A, Batat E, Yosef L, Shochat T, Goldstein DA, Dudnik E, Spectre G, Raanani P, Hammerman A, Zer A. Arterial and venous thromboembolism in ALK-rearrangement-positive non-small cell lung cancer: a population-based cohort study. Oncologist. 2023;28(6):e391-6.","journal-title":"Oncologist"},{"issue":"2","key":"281_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cllc.2016.10.007","volume":"18","author":"A Zer","year":"2017","unstructured":"Zer A, Moskovitz M, Hwang DM, Hershko-Klement A, Fridel L, Korpanty GJ, Dudnik E, Peled N, Shochat T, Leighl NB, Liu G, Feld R, Burkes R, Wollner M, Tsao MS, Shepherd FA. ALK-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism. Clin Lung Cancer. 2017;18(2):156\u201361.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"281_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12931-020-01437-6","volume":"21","author":"W Xiong","year":"2020","unstructured":"Xiong W, Du H, Ding W, Sun J, Xu M, Guo X. The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC. Respir Res. 2020;21(1):185.","journal-title":"Respir Res"},{"issue":"3","key":"281_CR28","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/jth.15215","volume":"19","author":"J Roopkumar","year":"2021","unstructured":"Roopkumar J, Poudel SK, Gervaso L, Reddy CA, Velcheti V, Pennell NA, McCrae KR, Khorana AA. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: a cohort study. J Thromb Haemost. 2021;19(3):822\u20139.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"281_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.jtho.2020.04.033","volume":"15","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Leiva O, Dagogo-Jack I, Shaw A, Lennerz J, Iafrate AJ, Bendapudi PK, Connors JM. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J Thorac Oncol. 2020;15(9):1497\u2013506.","journal-title":"J Thorac Oncol"},{"key":"281_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.lungcan.2021.05.019","volume":"157","author":"VW Zhu","year":"2021","unstructured":"Zhu VW, Zhao JJ, Gao Y, Syn NL, Zhang SS, Ou SI, Bauer KA, Nagasaka M. Thromboembolism in ALK+ and ROS1+ NSCLC patients: a systematic review and meta-analysis. Lung Cancer. 2021;157:147\u201355.","journal-title":"Lung Cancer"},{"key":"281_CR31","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.3390\/ijms252111354","volume":"25","author":"DM Kowalski","year":"2024","unstructured":"Kowalski DM, Zaborowska-Szmit M, Bryl M, Byszek A, Dziedzic DA, Ja\u015bkiewicz P, Langfort R, Krzakowski M, Or\u0142owski T, Ramlau R, Szmit S. The detailed analysis of Polish patients with non-small cell lung cancer through insights from molecular testing (POL-MOL Study). Int J Mol Sci. 2024;25:11354. https:\/\/doi.org\/10.3390\/ijms252111354.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"281_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd3252","volume":"10","author":"T Force","year":"2011","unstructured":"Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10(2):111\u201326.","journal-title":"Nat Rev Drug Discov"},{"issue":"16","key":"281_CR33","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1158\/1078-0432.CCR-09-0802","volume":"15","author":"SJ Rodig","year":"2009","unstructured":"Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E, Janne PA, Lynch T, Johnson BE, Iafrate AJ, Chirieac LR. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216\u201323.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"281_CR34","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, Settleman J, Kobayashi S, Mark EJ, Rodig SJ, Chirieac LR, Kwak EL, Lynch TJ, Iafrate AJ. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247\u201353.","journal-title":"J Clin Oncol"},{"issue":"8","key":"281_CR35","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-10-1591","volume":"17","author":"AT Shaw","year":"2011","unstructured":"Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17(8):2081\u20136.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"281_CR36","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F, PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167\u201377.","journal-title":"N Engl J Med"},{"issue":"9","key":"281_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, P\u00e9rol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T, ALEX Trial Investigators. Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829\u201338.","journal-title":"N Engl J Med"},{"issue":"21","key":"281_CR38","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","volume":"379","author":"DR Camidge","year":"2018","unstructured":"Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027\u201339.","journal-title":"N Engl J Med"},{"issue":"29","key":"281_CR39","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","volume":"42","author":"BJ Solomon","year":"2024","unstructured":"Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Lorlatinib Versus Crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol. 2024;42(29):3400\u20139.","journal-title":"J Clin Oncol"},{"issue":"5","key":"281_CR40","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1200\/JCO.22.02124","volume":"41","author":"DH Owen","year":"2023","unstructured":"Owen DH, Singh N, Ismaila N, Blanchard E, Celano P, Florez N, Jain D, Leighl NB, Mamdani H, Masters G, Moffitt PR, Naidoo J, Phillips T, Riely GJ, Robinson AG, Schenk E, Schneider BJ, Sequist L, Spigel DR, Jaiyesimi IA. Therapy for stage IV Non-small-cell lung cancer with driver alterations: ASCO living guideline, version 2022.2. J Clin Oncol. 2023;41(5):e10\u201320.","journal-title":"J Clin Oncol"},{"issue":"1","key":"281_CR41","first-page":"CD013453","volume":"1","author":"LB Cameron","year":"2022","unstructured":"Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022;1(1):CD013453.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"281_CR42","doi-asserted-by":"publisher","first-page":"101560","DOI":"10.1016\/j.esmoop.2023.101560","volume":"8","author":"F Zhou","year":"2023","unstructured":"Zhou F, Yang Y, Zhang L, Cheng Y, Han B, Lu Y, Wang C, Wang Z, Yang N, Fan Y, Wang L, Ma Z, Zhang L, Yao Y, Zhao J, Dong X, Zhu B, Zhou C. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors. ESMO Open. 2023;8(3):101560.","journal-title":"ESMO Open"},{"issue":"3","key":"281_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5603\/OCP.2023.0011","volume":"19","author":"M Gil","year":"2023","unstructured":"Gil M, Chmielewska I, Krawczyk P, Nizi\u0144ski P, Strzemski M, Milanowski J. Replacement of ALK inhibitors as an effective strategy for reducing drug toxicity in non-small cell lung cancer patients with ALK gene rearrangement. Oncol Clin Pract. 2023;19(3):190\u20136.","journal-title":"Oncol Clin Pract"},{"issue":"3","key":"281_CR44","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.3390\/curroncol30030230","volume":"30","author":"TF Wang","year":"2023","unstructured":"Wang TF, Carrier M. Immune checkpoint inhibitors-associated thrombosis: incidence, risk factors and management. Curr Oncol. 2023;30(3):3032\u201346.","journal-title":"Curr Oncol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-024-00281-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T06:03:49Z","timestamp":1731132229000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-024-00281-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1186\/s40959-024-00281-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Bioethical Committee of the Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland: opinion number 6\/2024, date: January 18th, 2024.The patients did not sign informed consent to participate in the study, because it based on retrospectively collected administrative data from the National Research Institute of Oncology in Warsaw, Poland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}